4 Mergers and Acquisitions Stock Stories Making Monday Headlines

BlackBerry Ltd. (NASDAQ:BBRY): Current price $10.89

A number of private equity executives believe that an arrangement to take BlackBerry private might be logical from a financial standpoint, although any such move would not make the smartphone firm any more competitive. Following a weekend Reuters report that BlackBerry’s board was getting closer to the possibility of going private as it struggles to revive its fortunes, executives said that the figures for a leveraged buyout could still work.

Are these stocks a buy or sell? Let us help you decide. Check out our Stock Picker Newsletter now.

BBRY 20130812

Rockwell Collins Inc. (NYSE:COL): Current price $73.06

Rockwell on Monday said it will purchase Arinc Inc., a portfolio firm of The Carlyle Group and a provider of communications and information processing solutions for the commercial aviation industry, at a price of $1.39 billion. The agreement will unite leading players in the field of aviation information management, combining Arinc’s networks and services with the industry-leading avionics and cabin technologies developed by Rockwell Collins, according to a company release. The transaction should close upon receipt of regulatory approvals and other usual conditions.

Are these stocks a buy or sell? Let us help you decide. Check out our Stock Picker Newsletter now.

COL 20130812

Pinnacle Foods (NYSE:PF): Current price $26.47

Pinnacle announced Monday that it will acquire the Wish-Bone salad dressings division from Unilever PLC in a transaction that should be immediately accretive to the buyer. The purchase, which is subject to customary closing conditions, is anticipated to be finished in late third or early fourth quarter.

Are these stocks a buy or sell? Let us help you decide. Check out our Stock Picker Newsletter now.

PF 20130812

Quest Diagnostics Inc. (NYSE:DGX): Current price $59.50

Royalty Pharma said Monday that through a collaboration with Aisling Capital and Clarus Ventures it has divested to the latter firms about 20 percent of the royalty interest in ibrutinib it recently bought from Quest Diagnostics for a pro rata percentage of the $485 million that Royalty Pharma paid to Quest for the royalty.

Are these stocks a buy or sell? Let us help you decide. Check out our Stock Picker Newsletter now.

DGX 20130812

Don’t Miss: BlackBerry Considering Its Options, Even the Auction Block.

More Articles About:   , , , ,  

More from The Cheat Sheet